Cargando…
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
Mantle cell lymphoma (MCL) is a rare mature B-cell non-Hodgkin lymphoma (B-NHL) with historically poor outcomes. Virtually all patients will eventually experience refractory or relapsed (R/R) disease, with a virulent course of resistance and serial relapses, making treatment challenging. The availab...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954159/ https://www.ncbi.nlm.nih.gov/pubmed/35330376 http://dx.doi.org/10.3390/jpm12030376 |
_version_ | 1784676026100482048 |
---|---|
author | Burkart, Madelyn Karmali, Reem |
author_facet | Burkart, Madelyn Karmali, Reem |
author_sort | Burkart, Madelyn |
collection | PubMed |
description | Mantle cell lymphoma (MCL) is a rare mature B-cell non-Hodgkin lymphoma (B-NHL) with historically poor outcomes. Virtually all patients will eventually experience refractory or relapsed (R/R) disease, with a virulent course of resistance and serial relapses, making treatment challenging. The available therapies for R/R MCL are not curative with conventional therapy, their goal being to palliate and prolong survival. A variety of agents approved for R/R MCL, including Bruton’s tyrosine kinase inhibitors (BTKi), changed the treatment landscape of R/R MCL. In the pre-BTKi era, the median progression-free survival (PFS) in R/R disease was 4–9 months. With the introduction of ibrutinib, the median PFS improved to 13–14.6 months. Despite these impressive results, the duration of response is limited, and resistance to BTKi inevitably develops in a subset of patients. Outcomes after progression on BTKi are extremely poor, with a median overall survival (OS) of 6 to 10 months. Certain therapies, such as chimeric antigen receptor (CAR) T cells, have shown promising results after BTKi failure. The preferred combination and sequencing of therapies beyond BTKi remain unestablished and are currently being investigated. In this review, we describe the current evidence for the available treatment of R/R MCL after progression on BTKi. |
format | Online Article Text |
id | pubmed-8954159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89541592022-03-26 Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors Burkart, Madelyn Karmali, Reem J Pers Med Review Mantle cell lymphoma (MCL) is a rare mature B-cell non-Hodgkin lymphoma (B-NHL) with historically poor outcomes. Virtually all patients will eventually experience refractory or relapsed (R/R) disease, with a virulent course of resistance and serial relapses, making treatment challenging. The available therapies for R/R MCL are not curative with conventional therapy, their goal being to palliate and prolong survival. A variety of agents approved for R/R MCL, including Bruton’s tyrosine kinase inhibitors (BTKi), changed the treatment landscape of R/R MCL. In the pre-BTKi era, the median progression-free survival (PFS) in R/R disease was 4–9 months. With the introduction of ibrutinib, the median PFS improved to 13–14.6 months. Despite these impressive results, the duration of response is limited, and resistance to BTKi inevitably develops in a subset of patients. Outcomes after progression on BTKi are extremely poor, with a median overall survival (OS) of 6 to 10 months. Certain therapies, such as chimeric antigen receptor (CAR) T cells, have shown promising results after BTKi failure. The preferred combination and sequencing of therapies beyond BTKi remain unestablished and are currently being investigated. In this review, we describe the current evidence for the available treatment of R/R MCL after progression on BTKi. MDPI 2022-03-01 /pmc/articles/PMC8954159/ /pubmed/35330376 http://dx.doi.org/10.3390/jpm12030376 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Burkart, Madelyn Karmali, Reem Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors |
title | Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors |
title_full | Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors |
title_fullStr | Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors |
title_full_unstemmed | Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors |
title_short | Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors |
title_sort | relapsed/refractory mantle cell lymphoma: beyond btk inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954159/ https://www.ncbi.nlm.nih.gov/pubmed/35330376 http://dx.doi.org/10.3390/jpm12030376 |
work_keys_str_mv | AT burkartmadelyn relapsedrefractorymantlecelllymphomabeyondbtkinhibitors AT karmalireem relapsedrefractorymantlecelllymphomabeyondbtkinhibitors |